Sam Fazeli

Right.

So if you were to quantify the... So there's two things you have understood here is the number of potential leads that you generate can be magnitudes, orders of magnitudes higher, but also the speed with which you generate them.

If you wanted to quantify the speed, how much faster are you getting to your potential lead versus standard methods?

That's interesting because if you recall, I did this thing trying to get a feel for innovation in China, looking at the number of possible first-in-class molecules that could come to market by 2030 with some obvious assumptions.

What I hadn't looked into is to try and classify these molecules or any pharma pipeline on novelty.

Because that's difficult and it depends a lot on your definitions.

But let's talk about this subject.

So the targets biology identifies.

Genes are thrown up in the biology or in the system or somehow.

The chemistry is also an extra angle here.

Now, you fish in the known chemical space, I suppose.

Correct me there.

No, no, no.

You mean, can you tell me what that would be?

Is that something, a molecule that wasn't known or characterized before in a pathway or?

So that's low novelty, but you can come up with a better drug.

So for novel targets, you need to take it through to proof of concept essentially in a phase two.

Exactly.

Okay.

And then in the chemistry space, in this warm molecule world, what took us through that?